ParkinsonFranceV1, PubMed, Corpus, bibRecord, 001391

Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.

Identifieur interne : 001391 ( PubMed/Corpus ); précédent : 001390; suivant : 001392

Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.

Auteurs : M P Muriel ; V. Bernard ; A I Levey ; O. Laribi ; D N Abrous ; Y. Agid ; B. Bloch ; E C Hirsch

Source :

Annals of neurology [ 0364-5134 ] ; 1999.

RBID : pubmed:10401786

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Animals, Corpus Striatum (metabolism), Humans, Immunohistochemistry, Male, Oxidopamine (metabolism), Parkinson Disease (metabolism), Rats, Rats, Wistar, Receptors, Dopamine D1 (metabolism).
MESH :
- chemical , metabolism : Oxidopamine, Receptors, Dopamine D1.
- metabolism : Corpus Striatum, Parkinson Disease.
- Aged, Aged, 80 and over, Animals, Humans, Immunohistochemistry, Male, Rats, Rats, Wistar.

Abstract

Parkinson's disease is characterized by a massive loss of nigral dopamine neurons that results in a reduction of dopamine concentrations in the striatum. The most commonly used treatment for this disease is levodopa therapy to restore striatal dopamine. This treatment is mediated by dopamine receptors, but the effect of treatment and the disease on receptor distribution is unknown. In this study, the distribution of D1 dopamine receptors was analyzed at the cellular and subcellular level in the striatum of 5 patients with Parkinson's disease (all treated with levodopa) and 4 control subjects. In the control brains, D1 dopamine receptors were mostly detected on the plasma membrane of medium-sized spiny neurons. The quantitative analysis performed at the ultrastructural level in patients with Parkinson's disease revealed an increase in immunostaining in the cytoplasm of medium-sized neurons. This effect was likely the result of the treatment rather than the dopaminergic denervation, as such changes were not observed in the striatum of rats with a unilateral 6-hydroxydopamine nigrostriatal lesion, but were present in normal or lesioned rats treated with a D1 dopamine agonist. Altered localization of D1 dopamine receptors may participate in the occurrence of side effects of levodopa therapy such as dyskinesia and fluctuations in motor performances.

PubMed: 10401786

Links to Exploration step

pubmed:10401786

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.</title>
<author><name sortKey="Muriel, M P" sort="Muriel, M P" uniqKey="Muriel M" first="M P" last="Muriel">M P Muriel</name>
<affiliation><nlm:affiliation>Institut National de la Santé et de la Recherche Médicale U289, Hôpital de la Salpêtrière, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bernard, V" sort="Bernard, V" uniqKey="Bernard V" first="V" last="Bernard">V. Bernard</name>
</author>
<author><name sortKey="Levey, A I" sort="Levey, A I" uniqKey="Levey A" first="A I" last="Levey">A I Levey</name>
</author>
<author><name sortKey="Laribi, O" sort="Laribi, O" uniqKey="Laribi O" first="O" last="Laribi">O. Laribi</name>
</author>
<author><name sortKey="Abrous, D N" sort="Abrous, D N" uniqKey="Abrous D" first="D N" last="Abrous">D N Abrous</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name>
</author>
<author><name sortKey="Bloch, B" sort="Bloch, B" uniqKey="Bloch B" first="B" last="Bloch">B. Bloch</name>
</author>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10401786</idno>
<idno type="pmid">10401786</idno>
<idno type="wicri:Area/PubMed/Corpus">001391</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001391</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.</title>
<author><name sortKey="Muriel, M P" sort="Muriel, M P" uniqKey="Muriel M" first="M P" last="Muriel">M P Muriel</name>
<affiliation><nlm:affiliation>Institut National de la Santé et de la Recherche Médicale U289, Hôpital de la Salpêtrière, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bernard, V" sort="Bernard, V" uniqKey="Bernard V" first="V" last="Bernard">V. Bernard</name>
</author>
<author><name sortKey="Levey, A I" sort="Levey, A I" uniqKey="Levey A" first="A I" last="Levey">A I Levey</name>
</author>
<author><name sortKey="Laribi, O" sort="Laribi, O" uniqKey="Laribi O" first="O" last="Laribi">O. Laribi</name>
</author>
<author><name sortKey="Abrous, D N" sort="Abrous, D N" uniqKey="Abrous D" first="D N" last="Abrous">D N Abrous</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name>
</author>
<author><name sortKey="Bloch, B" sort="Bloch, B" uniqKey="Bloch B" first="B" last="Bloch">B. Bloch</name>
</author>
<author><name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name>
</author>
</analytic>
<series><title level="j">Annals of neurology</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Corpus Striatum (metabolism)</term>
<term>Humans</term>
<term>Immunohistochemistry</term>
<term>Male</term>
<term>Oxidopamine (metabolism)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Rats</term>
<term>Rats, Wistar</term>
<term>Receptors, Dopamine D1 (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Oxidopamine</term>
<term>Receptors, Dopamine D1</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Humans</term>
<term>Immunohistochemistry</term>
<term>Male</term>
<term>Rats</term>
<term>Rats, Wistar</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease is characterized by a massive loss of nigral dopamine neurons that results in a reduction of dopamine concentrations in the striatum. The most commonly used treatment for this disease is levodopa therapy to restore striatal dopamine. This treatment is mediated by dopamine receptors, but the effect of treatment and the disease on receptor distribution is unknown. In this study, the distribution of D1 dopamine receptors was analyzed at the cellular and subcellular level in the striatum of 5 patients with Parkinson's disease (all treated with levodopa) and 4 control subjects. In the control brains, D1 dopamine receptors were mostly detected on the plasma membrane of medium-sized spiny neurons. The quantitative analysis performed at the ultrastructural level in patients with Parkinson's disease revealed an increase in immunostaining in the cytoplasm of medium-sized neurons. This effect was likely the result of the treatment rather than the dopaminergic denervation, as such changes were not observed in the striatum of rats with a unilateral 6-hydroxydopamine nigrostriatal lesion, but were present in normal or lesioned rats treated with a D1 dopamine agonist. Altered localization of D1 dopamine receptors may participate in the occurrence of side effects of levodopa therapy such as dyskinesia and fluctuations in motor performances.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10401786</PMID>
<DateCreated><Year>1999</Year>
<Month>08</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>1999</Year>
<Month>08</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN>
<JournalIssue CitedMedium="Print"><Volume>46</Volume>
<Issue>1</Issue>
<PubDate><Year>1999</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Annals of neurology</Title>
<ISOAbbreviation>Ann. Neurol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>103-11</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Parkinson's disease is characterized by a massive loss of nigral dopamine neurons that results in a reduction of dopamine concentrations in the striatum. The most commonly used treatment for this disease is levodopa therapy to restore striatal dopamine. This treatment is mediated by dopamine receptors, but the effect of treatment and the disease on receptor distribution is unknown. In this study, the distribution of D1 dopamine receptors was analyzed at the cellular and subcellular level in the striatum of 5 patients with Parkinson's disease (all treated with levodopa) and 4 control subjects. In the control brains, D1 dopamine receptors were mostly detected on the plasma membrane of medium-sized spiny neurons. The quantitative analysis performed at the ultrastructural level in patients with Parkinson's disease revealed an increase in immunostaining in the cytoplasm of medium-sized neurons. This effect was likely the result of the treatment rather than the dopaminergic denervation, as such changes were not observed in the striatum of rats with a unilateral 6-hydroxydopamine nigrostriatal lesion, but were present in normal or lesioned rats treated with a D1 dopamine agonist. Altered localization of D1 dopamine receptors may participate in the occurrence of side effects of levodopa therapy such as dyskinesia and fluctuations in motor performances.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muriel</LastName>
<ForeName>M P</ForeName>
<Initials>MP</Initials>
<AffiliationInfo><Affiliation>Institut National de la Santé et de la Recherche Médicale U289, Hôpital de la Salpêtrière, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bernard</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y"><LastName>Levey</LastName>
<ForeName>A I</ForeName>
<Initials>AI</Initials>
</Author>
<Author ValidYN="Y"><LastName>Laribi</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Abrous</LastName>
<ForeName>D N</ForeName>
<Initials>DN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Agid</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bloch</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hirsch</LastName>
<ForeName>E C</ForeName>
<Initials>EC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Ann Neurol</MedlineTA>
<NlmUniqueID>7707449</NlmUniqueID>
<ISSNLinking>0364-5134</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber>
<NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Neurol. 2000 Jan;47(1):136-7</RefSource>
<PMID Version="1">10632116</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year>
<Month>7</Month>
<Day>13</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2000</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1999</Year>
<Month>7</Month>
<Day>13</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10401786</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001391 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001391 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:10401786
   |texte=   Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:10401786" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.

Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki